Successful autologous peripheral blood stem cell transplantation in a Jehovah’s Witness with multiple myeloma: review of literature and recommendations for high-dose chemotherapy without support of allogeneic blood products
We present a case report of a successful high-dose melphalan therapy and autologous stem cell transplantation without the use of allogeneic blood product support in a 70-year-old patient suffering from multiple myeloma. Based on the experience in this case and thorough evaluation of the literature,...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
4 March 2008
|
| In: |
International journal of hematology
Year: 2008, Jahrgang: 87, Heft: 3, Pages: 289-297 |
| ISSN: | 1865-3774 |
| DOI: | 10.1007/s12185-008-0055-x |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s12185-008-0055-x
|
| Verfasserangaben: | S. Schmitt, V. Mailaender, G. Egerer, A. Leo, S. Becker, P. Reinhardt, M. Wiesneth, H. Schrezenmeier, A.D. Ho, H. Goldschmidt, T.M. Moehler |
| Zusammenfassung: | We present a case report of a successful high-dose melphalan therapy and autologous stem cell transplantation without the use of allogeneic blood product support in a 70-year-old patient suffering from multiple myeloma. Based on the experience in this case and thorough evaluation of the literature, we consider pre-transplant Hb level of 11-12 g/dl, platelet count higher than 70/nl, good WHO performance status of two and lower and informed consent as important eligibility criteria. During cytopenia recommended supportive measures include growth factor support with erythropoietin and G-CSF, p.o. iron treatment as well as prophylactic use of anti-fibrinloytic agents. Furthermore we discuss additional options that might be considered depending on the individual factors as e.g. pre-transplant collection and cryoconservation of autologous platelet concentrates. Moreover, an analysis of socio-economic issues regarding this procedure is presented. We conclude that allogeneic blood product free transplantation is a feasible procedure that can be offered to the patients belonging to distinct religious groups refusing allogeneic blood products as Jehova´s Witnesses and patients presenting other contraindications for transfusions. |
|---|---|
| Beschreibung: | Gesehen am 13.10.2021 |
| Beschreibung: | Online Resource |
| ISSN: | 1865-3774 |
| DOI: | 10.1007/s12185-008-0055-x |